The Calendar Under the Seat

Capture Corner is the premium BD intelligence companion to Mission Meets Tech. Public-record sourced. Independent analysis. Not a recommendation, not vendor advocacy, not capture material. Built for federal health BD, capture, and proposal leaders who need analytical depth, not headlines.

This issue is the companion to "The Man Who Publishes His Plan," published this week. The public piece reads Matt Clark's record. This one works the calendar underneath the seat he takes at the end of the month: where milestone and award authority now sits inside DHA, the phase gates on the enterprise Commercial Solutions Opening and its first area of interest, every vehicle in the portfolio that reaches a decision point inside calendar 2027, the evaluation logic a product-development executive brings to a ten-page white paper, and the teaming and size-status exposures that have already cost bidders awards this year.

---

1. The picture at a glance

Field	Detail
Incoming executive	Matt Clark, Assistant Director for Research, Development, and Acquisition and Component Acquisition Executive, effective end of September 2026 per his own announcement [CC1]
Seat as advertised	Oversight of all medical acquisition and medical research and development for the Department, annual acquisition and procurement spend of $2.3 billion; announcement closed March 23, 2026 [CC2]
Structure beneath the seat	Three portfolio acquisition executives (Medical Products, Medical Services, Medical Digital Solutions) plus a research and development directorate of more than 1,500 staff transferred from Army MRDC in 2024 [CC3][CC4]
Statutory driver	FY2026 NDAA Sec. 1802, 10 U.S.C. 1732, portfolio acquisition executives; conversion of program executive offices due by December 2027 [CC5]
Primary entry vehicle	Enterprise-wide Commercial Solutions Opening HT003826SC005, posted August 2026, usable by any PAE or program office [CC6]
First competitive area of interest	HT003826SC005-AOI0001, PAE Medical Digital Solutions End User Services (AWACS), presolicitation posted August 30, 2026 [CC7][CC8]
Parallel CSO in source selection	ESS Next, HT003826SC003, Phase 1 closed August 20, 2026, fixed-price only, contractor-drafted PWS at Phase 2 [CC9]
Largest 2027 event	MHS GENESIS integrator teardown: five sole-source platform contracts, Oracle Health direct by November 2026, Henry Schein and Solventum by July 2027, competed services layers to follow [CC10]
Hardest 2027 cliff	Workforce 3.0 ordering period closes January 2027; CTO5 sole-source justification to BCG Federal issued July 31, 2026; no successor solicitation located [CC11]
Nearest small business door	OMNIBUS IV 8(a) on-ramp RFP expected late September 2026; base ordering period ends June 19, 2027; $10 billion ceiling; 51 task orders, 33 to small business [CC12]

Confidence: High on the appointment, the seat description, the statute, and every solicitation date and phase structure above, read from the announcement, the position posting, the public law, and the SAM.gov and trade records. Medium on the reporting arrangement for PEO DHMS and the internal governance bodies in Section 2, which rest on my own April and May analysis and on secondary sources, with no published Department memo located. Medium on contract values throughout, which come from award aggregators and trade coverage; verify in the federal award record before pricing against them.

The lead finding for a capture team: the man who takes the acquisition executive seat on September 30 will be signing decisions on a vehicle built for prototype-to-production buying, in the same quarter that DHA's largest services IDIQ stops accepting orders, its EHR integrator relationship gets split into direct platform contracts, and its research vehicle opens an 8(a) door. Every one of those is a phase-gated competition where a short white paper is the first and often the only artifact that gets read, and the reader has published, over eight years, exactly what he looks for in one.

---

2. Where decision authority sits after September 30

Confidence: Medium. The statute and the seat posting are primary. The internal arrangement is my reconstruction from the April 20 reorganization and later releases.

The Component Acquisition Executive owns milestone and portfolio decisions for DHA acquisition and delegates through three portfolio acquisition executives to program and product managers. The enterprise CSO confirms the three portfolio names and states that any PAE or program office can use it. [CC6] A Portfolio Acquisition Executive for Medical Digital Solutions was posted as an SES vacancy this year, and the first competitive area of interest under the CSO issued under that PAE's banner, which is the clearest public evidence the structure is operating. [CC7]

Two constraints bind the seat from outside the agency and both matter to a bid.

Commercial-first memorandum. Sec. 1822 of the FY2026 NDAA requires the contracting officer and the portfolio acquisition executive to submit a written memorandum before using non-commercial solicitation procedures. [CC5][CC13] The burden of justification now sits on the government when it wants to buy government-unique. A vendor that can show commercial customers, commercial pricing history, and a commercial roadmap is procedurally easier to buy than one that needs a PAE's signature on a justification. The enterprise CSO's own language says DHA will prioritize commercially available solutions over government-unique development. [CC6]

The contracting activity. Every award instrument runs through the DHA Contracting Activity, whose director has obligated more than $20 billion a year across the agency's portfolio. [CC14] Nothing the new executive wants to change about how DHA buys reaches an award without DHACA executing it, which makes the head of contracting activity the single most consequential working relationship in the building and the one to watch for procedural signals such as J&A cadence and CSO area-of-interest tempo.

PEO DHMS. As I reported in May, the reported arrangement is a hybrid: PEO DHMS retains executive decision authority over DHMSM, JOMIS, and EIDS while its reporting moves under the assistant director. [CC15] That rests on my own analysis and a fact sheet, with no Department memo located, so treat it as reported. If it holds, the largest programs in the account report to the new executive without being decided by him, which means the GENESIS teardown is a program he oversees and PEO DHMS executes.

Requirements. Requirements generation moved into a named J-9 function under operations and training in the April reorganization, and JCIDS was disestablished department-wide by the November 7, 2025 memo. [CC15] For a capture team the practical consequence is that operational need statements now originate in an office that sits beside acquisition, outside the buying chain, and that is the office to be in front of for anything that will be a requirement eighteen months out.

---

3. The vehicle, gate by gate

Confidence: High on the solicitation records. Medium on the AWACS page limits, which come from an aggregator's read of the solicitation package.

HT003826SC005, the enterprise CSO. A standing vehicle that will carry many requirements over its life. Phase structure: a brief white paper or pitch, an optional demonstration, then an invitation to selected offerors for a full proposal. Multiple awards possible per area of interest. The CSO preserves DHA's ability to award sole-source follow-on production agreements for successfully completed prototype efforts where statute allows. [CC6]

That last clause is the single most valuable structural feature of the vehicle. It converts a modest prototype agreement into a potential production position without a further competition, and the incoming executive has run that exact sequence. Kaléo's ROCS prototype went through the Medical CBRN Defense Consortium, the FDA approved the product on February 28, 2022, and the production agreement for up to 788,000 auto-injectors was executed as the follow-on to the prototype effort. [CC16][CC17] Price a prototype award under this CSO as an option on a production line.

HT003826SC005-AOI0001, AWACS. The first competitive area of interest, issued under PAE Medical Digital Solutions for end-user services across the PEO DHMS portfolio. The June industry day described a firm-fixed-price, outcome-based, centralized shared-services model on ServiceNow supporting roughly 125,000 to 150,000 active clinical and operational users and 9.5 million beneficiaries across eight service pillars and eleven user domains, replacing legacy labor-intensive support contracts, with a three-day clinical onboarding pipeline as a stated target. [CC8] The presolicitation posted August 30, 2026, and subcontracting sub-scopes carved from it carry mid-September response dates. [CC7] Aggregator reads of the package describe a Phase 1 white paper capped at ten pages plus a two-page continuity crosswalk, on roughly a ten-day response window. [CC18]

The continuity crosswalk requirement is itself a signal. DHA is buying transition risk reduction as much as capability, and a team that cannot document how it inherits an operating environment without a service gap will not clear Phase 1 regardless of solution quality.

HT003826SC003, ESS Next. Released August 5, 2026 for PEO DHMS enterprise support and software services; Phase 1 closed August 20. Awards will be fixed-price and tied to results, with DHA stating it cannot award on a level-of-effort or labor-hour basis. Phase 2 requires the contractor to draft the performance work statement and price it. Evaluation factors as reported: advancement, with solutions that do not represent a meaningful improvement ineligible for award; efficacy and outcomes linked to the proposed pricing structure; technical approach and adaptability; and price at Phase 2 only. Multiple awards anticipated. [CC9]

Read those four factors as the template for every area of interest that follows. The first factor screens on whether the offer changes anything. The second ties outcomes to price. Price on its own does not appear until Phase 2. That ordering is what a product-development executive means when he says effects come first.

---

4. The decision calendar through 2027

Confidence: High on dates read from SAM.gov, the public law, and primary trade reporting. Medium on items marked reported.

When	Event	Capture consequence
Sept 2026, mid-month	AWACS AOI0001 sub-scope responses due; prime Phase 1 window running [CC7][CC18]	Teams that are not already formed miss the first competition under the new vehicle
Sept 30, 2026	Clark assumes the AD RDA / CAE seat [CC1]	First signatures on milestone decisions; watch for a portfolio review announcement
Late Sept 2026	OMNIBUS IV 8(a) on-ramp RFP expected, delayed from May for FAR overhaul guidance [CC12]	The clearest small business entry point on the calendar; multiple awards anticipated
Nov 2026	Oracle Health transitions to a direct sole-source platform contract, out from under the Leidos integrator relationship [CC10]	The EHR platform relationship becomes a government-to-OEM contract; services layers get competed separately
Dec 11, 2026	Current continuing resolution, P.L. 119-103, expires (reported) [CC19]	Full-year CR would leave the new PSCP account without a prior-year appropriation to continue and would repeat the FY2025 CDMRP cut
Dec 2026	TRICARE T-5 Option Period Three decision for CY2027 (reported; OP2 to Humana was $7.34 billion for CY2026) [CC20]	Purchased care remains the dollar center of gravity; closed to new entrants without a prime relationship
Jan 2027	Workforce 3.0 ordering period closes; CTO5 sole-source J&A to BCG Federal issued July 31, 2026; DTO5 design task awarded HT003826FE007 [CC11]	Roughly $1.4 billion of managed-services demand with no successor vehicle located; the successor strategy is the first big services call the new executive owns
FY2027, first half	ESS Next awards expected after Phase 2 [CC9]	Fixed-price enterprise support with contractor-drafted PWS; first proof of how the phase-gate model prices
June 19, 2027	OMNIBUS IV base ordering period ends; option ordering period June 20, 2027 through June 19, 2032 [CC12]	Option decision inside the executive's first year; on-ramp awardees compete for task orders from here
July 2027	Henry Schein and Solventum transition to direct contracts; GENESIS restructure targeted complete [CC10]	Up to five competed services procurements land inside a twelve to fifteen month window ending here
July 19, 2027	Enterprise Assurance and Security Support Services potential end date; incumbent graduates 8(a) September 2026 (reported) [CC21]	Recompete forced by size status
Aug 2027	DML-ES Core fully transitions to LogiCole (reported); DMLSS fourth-generation award terminated one day after award in January 2026 on size grounds [CC22]	Open medical logistics requirement with an industrial-base tailwind and a new executive who co-wrote the doctrine

Three reads for a pipeline.

First, the compression is real. Between the executive's first day and the end of his first year, the services IDIQ cliff, the EHR restructure, the research vehicle option, and two logistics transitions all land. He does not get a quiet quarter to learn the account, and the community should not expect one.

Second, the Workforce 3.0 successor is the decision to watch above the others. Six awardees, a $1.425 billion vehicle ceiling, BCG Federal at roughly $794 million obligated against a $955 million contract ceiling, a one-bidder $180.5 million core task order in 2025, and a July 2026 justification for another logical follow-on. [CC11] Whatever replaces it will be the first large services strategy written under a product-development executive, and its shape will tell you whether the outcome-priced, consolidated-vehicle direction of AWACS and ESS Next is the house style or a PEO DHMS preference.

Third, the OMNIBUS IV on-ramp lands the same week he does. Fifty-six original awardees, more than $600 million across 51 task orders, 94 percent of them issued in FY2024 through FY2026, 33 to small businesses, eight set aside for 8(a) and nine awarded to 8(a) participants. [CC12] It is the working small business channel in the portfolio, and it sits in the research directorate he now oversees.

---

5. The white paper rubric, built from his record

Confidence: Medium. This is my construction from published statements and the ESS Next evaluation factors. He has not published an evaluation guide.

A Phase 1 submission under the enterprise CSO is scored by a portfolio executive and a program office, with the CAE above them. The record gives you the reader's priors.

Rubric element	Where it comes from	What clears it
Effect before solution	"Decisive effects" is his first word; the Director told industry solutions are secondary to outcomes [CC1][CC23]	Paragraph one names the operational effect and the measure; the product appears second
Resource-linked schedule	"To be effective, you need to develop a resource-linked schedule and stick to it" [CC24]	Every milestone carries the resources that deliver it; a date without resourcing logic reads as risk
Knowledge points and off-ramps	2019 ROCS essay: knowledge points that inform acceleration or termination decisions sooner; explicit contrast with the acquisition waterfall [CC25]	The paper proposes its own decision gates and names the condition that would stop the effort
Meaningful improvement	ESS Next factor one: solutions without a meaningful improvement are ineligible [CC9]	The paper states what changes against the current state, in the government's terms
Outcomes tied to price	ESS Next factor two [CC9]	Outcome measures and pricing structure are one table, not two sections
Supply chain and industrial base	Military Review, July 2025: stockpiling, S&OP, vendor-managed inventory, onshoring, traceability, 30 percent domestic antibiotic sourcing by 2030 [CC26]	For products, tier two and three sourcing, surge capacity, and provenance in the first three pages
Commercial viability	Countering WMD Journal, 2025: commercial viability as the engine; industry needs predictability to invest [CC27]	A business case that survives the end of the government order: allied demand, dual use, BARDA or DTRA adjacency
A stated failure	Self-audit published in Defense Acquisition, 2024; "We will share failures, the outcomes require it" [CC1][CC28]	One honest lesson learned, specific, with what changed
Regulatory literacy	Career spent with the FDA as customer of record; thirteen-plus approved products [CC26][CC29]	For anything clinical, the regulatory pathway named and the pre-submission cadence planned

Two cautions. No public statement by Clark on artificial intelligence policy or AI acquisition was located, so a paper that pitches to an assumed AI doctrine is guessing; pitch ambient documentation or decision support on its documented DHA justification of clinician burden and human-in-the-loop governance. And no document was located in which he uses the term Commercial Solutions Opening. His fluency with flexible instruments, middle-tier authority, and consortium agreements is documented. His enthusiasm for CSOs specifically is an inference, and it should not appear in a capture brief as his statement.

---

6. The products tilt and where the money is

Confidence: High on the budget figures, read from the FY2027 justification books. Medium on the tilt itself, which is inference.

The dollars and the attention are in different places this year, and that gap is the opportunity.

The digital portfolio holds the money. Information Management rises $328.4 million to $2.600 billion in the FY2027 request, the largest increase in the operations account, and it is where AWACS, ESS Next, and the GSP task orders flow. [CC30] COMP procurement is $366.728 million. [CC30] Purchased care is $22.175 billion and closed to anyone without a prime relationship. [CC30]

The growth is in operational medicine and products. Three service field-medical procurement lines total $376.3 million in FY2027 against $97.9 million two years earlier, which is more than the entire COMP procurement account. [CC30] The House FY2027 mark would give the DHA Director authority to use COMP and Army medical readiness funds for medical countermeasure procurement, pre-positioning, forward deployment, logistics, storage, and sustainment (proposed, not law). [CC31] DLA's ARMOR wargame in July 2026 stress-tested the medical supply chain with more than 120 federal and industry partners and surfaced foreign dependencies and production limits. [CC32]

Now put the executive's record on top of that. Every documented success in it is FDA-regulated materiel: ROCS, the atropine auto-injector, midazolam, VAMP, the armored ambulance. [CC16][CC24][CC25][CC33] His co-authored doctrine paper re-justifies medical logistics as a war-reserve and industrial-base problem. [CC26] My read is that his personal attention concentrates on Medical Products and medical logistics while Medical Digital Solutions keeps the dollar volume and PEO DHMS keeps the decisions on the largest programs. Firms with a products or logistics story therefore have an unusually favorable attention-to-dollar ratio in FY2027, and firms with a digital story are competing in a portfolio the executive oversees at a distance.

The likely FY2027 posture, stated as inference: regulatory-pathway literacy becomes a discriminator in a portfolio where recent competition rewarded software delivery method; industrial-base and supply-chain requirements migrate from white papers into evaluation factors and CDRLs; and the reported valley of death between funded medical prototypes and programs of record becomes a named target, since it is the exact problem his middle-tier, knowledge-point method was built to attack.

---

7. Teaming, conflicts, and the mid-tier squeeze

Confidence: Medium. Aggregator and trade sourced; verify each award status before acting.

Three exposures are newly acute and two of them have already cost bidders awards this year.

Advisory-versus-competitor. Swingtide holds a sole-source market intelligence, acquisition advisory, and source-selection support role on the GENESIS restructure, reported extended fourteen months in August 2026, and AIX Tech holds a $225 million DHA contracting and acquisition support IDIQ with ordering through June 2031. [CC34] Map the organizational conflict of interest boundary before a Phase 1 submission, because a discovery at Phase 2 is a withdrawal.

OEM-versus-integrator. The GENESIS teardown creates five direct platform relationships plus up to five competed services procurements, and DHA has said its reasons include eliminating pass-through costs and duplicative layers of management. [CC10] A services bidder teamed with one of the five OEMs gains platform access and inherits the appearance of privileged knowledge; a services bidder teamed with none may lack the depth to bid. Leidos loses the integrator role, keeps bridge work through the transition, and retains a seat on the $300 million Deployment Solutions IDIQ awarded this summer to twelve holders. [CC10][CC35] There is no standing answer; make the teaming call against a specific area of interest.

Size status as award risk. The DMLSS fourth-generation award to Aktarius was terminated one day after award in January 2026 when DHA determined the firm was no longer small under the NAICS code. Eagle Integrated Services graduates from 8(a) in September 2026 and is no longer small under NAICS 541611, which forces the Enterprise Assurance recompete. IRMAC Pacific's closing date was suspended by a NAICS appeal at SBA's Office of Hearings and Appeals. [CC21][CC22][CC36] Set-asides remain central to the portfolio, with a $2.4 billion total small business GSP vehicle, an 8(a) IRMAC, an 8(a) OMNIBUS IV on-ramp, and an SDVOSB DES 2, and status now disrupts awards after they are made. Re-certify your size position against every NAICS you intend to bid before the on-ramp RFP posts.

The squeeze. Services consolidate upward into fewer outcome-priced vehicles (RC3, AWACS, ESS Next) while software and product work disaggregates to direct OEM relationships (GENESIS). Both movements press on the mid-tier integrator and staff-augmentation position that historically sat between the OEM and the enterprise prime. A firm whose value proposition is integration labor is being displaced from above by consolidators and from below by direct OEM contracts. The product and prototype lanes are opening while the body-shop lanes close, and a firm in the middle should decide this fiscal year which of the two it is becoming.

---

8. The counterargument, stated fairly

Confidence: Medium. Analysis, not a document finding.

Four reasons a products-and-prototypes capture thesis could underperform in his first year.

The money argues against the tilt. Information Management carries $2.6 billion; COMP procurement carries $367 million. [CC30] An executive can prefer a portfolio without moving its budget, and a services firm positioned on AWACS or ESS Next will see more obligated dollars in FY2027 than a products firm positioned on a medical countermeasure.

The largest programs are decided elsewhere. If the reported PEO DHMS arrangement holds, DHMSM, JOMIS, and EIDS keep their own decision authority. [CC15] The GENESIS restructure was approved in April 2026 and its transitions were scheduled before his name went on the org chart. He inherits its outcome without having shaped its design.

Appropriations can freeze everything. The current continuing resolution runs to December 11, 2026, and a full-year CR would leave the new Private Sector Care Program account without a prior-year appropriation to continue, would not fund the $3.139 billion mandatory facilities request at all, and would repeat the FY2025 CDMRP outcome of roughly $650 million. [CC19] An acquisition executive cannot accelerate what Congress has not funded.

Execution capacity, not authority, is the binding constraint. GAO documented a projected shortfall exceeding 8,000 clinical military medical personnel, with shortfalls anticipated until at least 2027, and DHA reporting it could not hire civilians to fill the gap. [CC37] New buying authority does not staff a hospital, and the program offices that would run new prototypes are drawing from the same workforce.

The counter to the counter is the protest record. Every 2026 DHA protest located was dismissed within roughly two to five weeks of filing and none reached a merits sustain, against a governmentwide FY2025 sustain rate of 14 percent across 380 merits decisions. [CC38] The protest channel is not slowing DHA awards. For a bidder, that argues for putting the money into pre-award engagement, teaming, and the Phase 1 artifact, and little into post-award litigation, which is exactly the posture a phase-gated CSO rewards.

---

9. What to do in the next ninety days

Form the AWACS team this week or skip it. A ten-page white paper with a two-page continuity crosswalk on a ten-day window cannot be assembled from scratch. If the team is not already under agreement, put the effort into the second area of interest and watch this one for the evaluation pattern.

Re-certify size before the on-ramp posts. The OMNIBUS IV 8(a) RFP is expected in late September. Three DHA awards or competitions this year were disrupted by size status after the fact. Confirm your position against the on-ramp NAICS and against every NAICS on your FY2027 target list, in writing, before you spend on proposals.

Rewrite the Phase 1 template against the rubric in Section 5. Effect and measure in paragraph one; outcomes and pricing in one table; your own knowledge points and stop condition; supply chain in the first three pages if you sell products; one stated failure. This is a template change, not a pursuit-by-pursuit change, and it applies to every area of interest under HT003826SC005 for as long as the CSO stands.

Price prototype awards as production options. The CSO preserves sole-source follow-on production for successful prototypes. Build the production-phase pricing and the transition plan into the Phase 1 paper even where the area of interest does not ask for it, because the vehicle rewards offers that already know what production looks like.

Map OCI before teaming on anything GENESIS-adjacent. Swingtide's advisory role and AIX Tech's acquisition support IDIQ both sit inside the restructure. Decide which OEM, if any, you team with against a specific competed services procurement, and document the boundary before Phase 1.

Put a marker on the Workforce 3.0 successor. No solicitation exists. The ordering period closes in January. Whatever posts will be the first large services strategy written under the new executive, and the shape of it, single or multiple award, outcome-priced or labor-based, tells you whether AWACS and ESS Next are the house style. Ask the contracting officer during market research what the successor strategy is, in writing, this month.

Get in front of J-9 for anything eighteen months out. Requirements now originate in a named function that sits beside acquisition. A capability that is not a requirement yet gets shaped there, and the new executive's record says he reads requirements as effects with measures attached.

Watch the thread, then the org chart. He said in public that when positions and needs open, the community should be ready to deliver. The first named hires into DHA research, development, and acquisition from JPEO-CBRND and Army medical research tell you which portfolio gets his attention first. That is the leading indicator, and it will show up on LinkedIn before it shows up anywhere else.

---

Mary

Mission Meets Tech Premium

---

Next Capture Corner: scheduled for the next major federal health or defense-health opportunity in active capture. Subscribers will receive an alert when the next issue publishes.

Capture Corner is an independent intelligence product. It is not affiliated with the Defense Health Agency, the Department of War, or any company named here, and it is not connected to any offeror's bid strategy. Premium subscription includes access to the standing intelligence sidebar plus the searchable archive.

---

Sources

[CC1] Matt Clark, PhD, PMP, LinkedIn announcement, September 2026, republished at OrangeSlices AI, "Matt Clark named DHA Assistant Director for Research, Development, and Acquisition and the Component Acquisition Executive," September 3, 2026. Source for the appointment, the end-of-month effective date, the DELIVER Care objective, the share-failures line, and the be-ready-to-deliver line. https://orangeslices.ai/matt-clark-named-dha-assistant-director-for-research-development-and-acquisition-and-the-component-acquisition-executive/

[CC2] USAJOBS, Defense Health Agency, "Assistant Director, Support/Component Acquisition Executive," announcement closed March 23, 2026, as mirrored at Glassdoor. Source for the $2.3 billion annual acquisition and procurement spend and the scope of oversight. The original announcement has closed. https://www.glassdoor.com/job-listing/assistant-director-support-component-acquisition-executive-usa-jobs-JV_IC1130361_KO0,58_KE59,67.htm?jl=1010040944823

[CC3] Mission Meets Tech, "DHA Is Replacing How It Buys," April 29, 2026 Premium issue, and the May 12, 2026 acquisition synch deck references therein. Source for the three-portfolio structure under the CAE, the J-9 requirements function, and the Capability Trade Council. Author's own analysis; corroborated for portfolio names by the enterprise CSO at [CC6].

[CC4] DVIDS, Defense Health Agency, "Defense Health Agency Welcomes New Research and Development Workforce," June 6, 2024. Source for the transfer of more than 1,500 scientists, program managers, acquisition experts, and support personnel from Army MRDC under the assistant director's office. https://www.dvidshub.net/news/473246/defense-health-agency-welcomes-new-research-and-development-workforce

[CC5] National Defense Authorization Act for Fiscal Year 2026, Public Law 119-60, December 18, 2025, Sec. 1802 (10 U.S.C. 1732, portfolio acquisition executives) and Sec. 1822 (commercial-first memorandum requirement). https://www.congress.gov/119/plaws/publ60/PLAW-119publ60.pdf

[CC6] OrangeSlices AI, "DHA Opens Enterprise-Wide Commercial Solutions Opportunity," August 2026, describing HT003826SC005. Source for the standing vehicle, the three portfolio names, use by any PAE or program office, the white paper or pitch, optional demonstration, and full proposal phases, the sole-source follow-on production authority, and the commercial-over-government-unique language. https://orangeslices.ai/dha-opens-enterprise-wide-commercial-solutions-opportunity/

[CC7] FBO Daily archive of the SAM.gov presolicitation, "Portfolio Acquisition Executive, Medical Digital Solutions (PAE MDS) End User Services (EUS) Area of Interest Application, Workflow, Adoption, and Change Support (AWACS)," posted August 30, 2026; CLEATUS sub-scope listings carved from HT003826SC005-AOI0001 with September 14, 2026 response dates. https://www.fbodaily.com/archive/2026/08-August/30-Aug-2026/FBO-07948457.htm and https://www.cleat.ai/government/contracts/change-management-and-strategic-communications-k2o2

[CC8] SAM.gov RFI and industry day Q&A, "Program Executive Office, Defense Healthcare Management Systems (DHMS) End User Services (EUS)," June 2026, as summarized by SweetSpot. Source for the 125,000 to 150,000 active users, 9.5 million beneficiaries, eight service pillars, eleven user domains, ServiceNow platform, firm-fixed-price outcome-based model, three-day clinical onboarding pipeline, and the June 25 and June 29 response dates. https://console.sweetspotgov.com/federal-contracts/c8396513-2753-57a4-a8db-cc610363d392

[CC9] Washington Technology, "DHA wants out of the test infrastructure business it built," August 2026; ExecutiveGov, "DHA Seeks Commercial Fixes for PEO DHMS Test Infrastructure," August 2026; Singularity Capital Advisors mirror of the Washington Technology report. Source for the ESS Next CSO release of August 5, Phase 1 close of August 20, fixed-price-only awards, no level-of-effort or labor-hour basis, contractor-drafted PWS at Phase 2, the four evaluation factors, the ineligibility of solutions without meaningful improvement, and multiple awards anticipated. https://www.washingtontechnology.com/contracts/2026/08/dha-wants-out-test-infrastructure-business-it-built/415248/

[CC10] SAM.gov notice, "Sole Source to MHS GENESIS Solution providers," June 9, 2026; Washington Technology, "How DHA plans to end Leidos' run as the military's health record integrator," June 13, 2026; OrangeSlices AI, "DHA Outlines New Multi-Award Acquisition Strategy for MHS GENESIS," June 9, 2026; Washington Technology coverage of Leidos' second-quarter earnings call, August 2026. Source for the five sole-source platform vendors, firm-fixed-price outcome-based contracts of no more than five years, the transition targets of Philips and Amwell by end of July 2026, Oracle Health by November 2026, and Henry Schein and Solventum by July 2027, the competed services layers, the stated reasons including pass-through costs and duplicative management layers, three years of market research from 2023 to early 2026, and Leidos bridge contracts through the transition. https://sam.gov/workspace/contract/opp/947fe670c6184824a5def4e406548a8c/view

[CC11] HigherGov vehicle and IDV records for Workforce 3.0 and HT003822D0001; GovDash record of the July 31, 2026 justification for exception to fair opportunity, WF3_Lot1_CTO5_26; OrangeSlices AI award records for HT003825F0015 ($180.5 million, one bidder) and HT003826FE007 (DTO5 design task, $1 million). Source for the January 2027 close of the ordering period, the $955 million BCG Federal contract ceiling, the CTO5 logical follow-on justification, and the task order values. Obligation totals are aggregator figures; verify in the federal award record. https://www.highergov.com/vehicle/workforce-3-0-wf3-3093/ and https://discover.govdash.com/solicitations/019fb855-ecd9-74ae-a056-5128d47b4cb7--workforce-3-0-managed-solution-defense-healthcare-management-systems-wf3

[CC12] SAM.gov presolicitation, "On-Ramp for the Department of Defense OMNIBUS IV," January 2026; Washington Technology, "Army, DHA tee up on-ramps for $11B in tech services contracts," August 2026; ExecutiveGov, "DHA Issues OMNIBUS IV On-Ramp Pre-Solicitation Notice," January 13, 2026. Source for the base ordering period of June 20, 2022 through June 19, 2027, the option ordering period through June 19, 2032, the $10 billion ceiling, the 8(a) set-aside, multiple awards anticipated, the late September 2026 solicitation target and the FAR overhaul reason for delay, 56 original awardees, 51 task orders exceeding $600 million, 94 percent issued FY2024 through FY2026, 33 to small businesses, eight 8(a) set-asides, and nine awards to 8(a) participants. https://sam.gov/workspace/contract/opp/87d03cafa68e4eeb9ecd870fe636f405/view and https://www.washingtontechnology.com/contracts/2026/08/army-dha-tee-ramps-11b-tech-services-contracts/415514/

[CC13] Greenberg Traurig, "FY 2026 NDAA: The Substantial Impact of the Fiscal Year 2026 National Defense Authorization Act on Federal Procurement Law," February 2026. Source for the Sec. 1822 requirement that both the contracting officer and the portfolio acquisition executive submit a written memorandum before using non-commercial solicitation procedures. Not independently fetched this session. https://www.gtlaw.com/en/insights/2026/2/fy2026ndaa/fy-2026-ndaa-the-substantial-impact-of-the-fiscal-year-2026-national-defense-authorization-act-on-federal-procurement-law

[CC14] Defense Health Agency, biography of James E. Watkins, Director, DHA Contracting Activity and Head of Contracting Activity. Source for responsibility for award and administration of all DHA contracts with annual obligations exceeding $20 billion. Not independently fetched this session. https://dha.mil/About-DHA/Organizational-Structure/Bios/Mr-Watkins

[CC15] Mission Meets Tech, "DHA Is Replacing How It Buys and the Budget Already Voted," May 29, 2026; health.mil, PEO DHMS fact sheet, March 24, 2026. Source for the reported hybrid PEO DHMS arrangement, the November 7, 2025 JCIDS disestablishment memo, and the J-9 requirements function. Author's own analysis; no Department memo confirming the reporting arrangement was located. https://www.health.mil/Reference-Center/Fact-Sheets/2026/03/24/Program-Executive-Office-Defense-Healthcare-Management-Systems-Fact-Sheet

[CC16] Kaléo, "Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System," September 21, 2022. Source for the up to 788,000 unit contract, February 28, 2022 FDA approval, and delivery under budget and five months early. https://www.globenewswire.com/en/news-release/2022/09/21/2520123/0/en/Kal%C3%A9o-Announces-First-U-S-Department-of-Defense-Supply-Contract-for-the-Rapid-Opioid-Countermeasure-System-ROCS-Antidote-for-Ultra-Potent-Weaponized-Opioids.html

[CC17] Kaléo, "Kaléo Receives Inaugural Medical CBRN Defense Consortium Innovation Award," August 2025. Source for the prototype through the Medical CBRN Defense Consortium and the follow-on production agreement. https://kaleo.com/kaleo-receives-inaugural-medical-cbrn-defense-consortium-innovation-award-for-prototype-development-of-its-rapid-opioid-countermeasure-system-naloxone-hcl-injection-usp-antidote/

[CC18] GovDash record of the AWACS area of interest under HT003826SC005. Source for the reported Phase 1 white paper limit of ten pages plus a two-page continuity crosswalk on roughly a ten-day window. Aggregator read of the solicitation package; confirm page limits and dates against the SAM.gov package before submission. https://discover.govdash.com/solicitations/01a00126-eca0-7169-a1fc-168f2616413f--portfolio-acquisition-executive-medical-digital-solutions-pae-mds-end-user-servi

[CC19] CSIS, "Tracking FY 2027 Defense Appropriations, Reconciliation, and Supplemental Request"; Defense Health Research Consortium letter to the Senate on FY2027 defense research funding, 2026. Source for P.L. 119-103 running to December 11, 2026, the full-year CR mechanism affecting the new 0146D account and the $3.139 billion mandatory request, and the FY2025 CDMRP outcome of roughly $650 million. Reported; not independently fetched this session. https://www.csis.org/analysis/tracking-fy-2027-defense-appropriations-reconciliation-and-supplemental-request

[CC20] Department of War contract announcements, December 17, 2025, Humana Government Business option period two for CY2026 at $7,342,637,605. Source for the T-5 option cadence and the CY2027 decision timing. Reported; not independently fetched this session. https://www.war.gov/News/Contracts/Contract/Article/4362955/contracts-for-dec-17-2025/

[CC21] HigherGov contract record W81XWH22C0074, Enterprise Assurance and Security Support Services, Eagle Integrated Services. Source for the potential end date of July 19, 2027 and the September 2026 8(a) graduation. Reported; verify in the federal award record. https://www.highergov.com/contract/W81XWH22C0074/

[CC22] SAM.gov notices for DMLSS fourth-generation technical and integration services and the bridge to incumbent, 2026; health.mil, DML-ES Core fact sheet, February 19, 2025. Source for the January 29, 2026 award to Aktarius LLC, its January 30, 2026 termination on size grounds, the March 1 through June 30, 2026 bridge, and the August 2027 LogiCole transition. Reported; verify current status. https://sam.gov/workspace/contract/opp/faa323a0a60a4f60b2dcc157dbe31a8a/view and https://www.health.mil/Reference-Center/Fact-Sheets/2025/02/19/DMLES-Core

[CC23] DVIDS, "Data, technology, people vital for warfighter health advantage, says Defense Health Agency director," August 2026. Source for Via's DHITS remarks that solutions are secondary to outcomes and that DHA is soliciting commercial solutions through a faster process. https://www.dvidshub.net/news/572343/data-technology-people-vital-warfighter-health-advantage-says-defense-health-agency-director

[CC24] U.S. Army Acquisition Support Center, "Acquisition a 'perfect fit' for Army scientist," April 10, 2018. Source for the resource-linked schedule quotation, the 2006 armored ambulance requirement, and the nearly 700 vehicles fielded by 2008. https://www.army.mil/article/203584/acquisition_a_perfect_fit_for_army_scientist

[CC25] U.S. Army Acquisition Support Center, Clark and Feldman, "Middle Tier Acquisition Using Overlapping, Iterative, and Incremental Development," March 14, 2019. Source for knowledge points informing acceleration or termination, the waterfall contrast, consortium engagement before arraying activities, and the FY2022 approval prediction. https://asc.army.mil/web/news-middle-tier-acquisition-using-overlapping-iterative-and-incremental-development-a-faster-way-to-combat-opioid-exposure/

[CC26] Military Review, Lodi, Murray, Clark, and Reed, "Treating Medicine as Ammunition," July 2025. Source for the recommendations listed in Section 5 and for the author biography stating participation in or leadership of more than thirteen FDA-approved products. https://www.armyupress.army.mil/journals/military-review/online-exclusive/2025-ole/medicine-as-ammunition/

[CC27] Countering WMD Journal, Issue 29 (2025), Clark, Holloway, Dulin, Heine, and Miller, "Collaboration with Industry: The Solution for a Sustainable Posture for Biodefense and Global Health Security," pp. 84-91. Article and authorship confirmed from the issue table of contents; the commercial viability quotation is as carried in prior research and was not read from the article text this session. https://www.usanca.army.mil/Portals/114/CWMD_Journal/Issue%2029%20Web%20Edition.pdf

[CC28] Defense Acquisition magazine, Atkinson, Zerhusen, and Clark, "Re-energizing Integrated Product Team Excellence in a Post-Pandemic Environment," September-October 2024. Source for the self-audit and published results. https://www.waru.edu/library/damag/sept-oct2024/re-energizing-integrated

[CC29] Matt Clark, LinkedIn post on departing JPM CBRN Medical, May 2025. Source for his own count of a seventh FDA approval in three years and ten in eight years. https://www.linkedin.com/posts/mgclarkphd_i-am-so-very-grateful-to-have-been-a-part-activity-7328727375758659585-x5Rv

[CC30] Department of War, Military Health System FY2027 Budget Estimates, Combat and Operational Medicine Program and Private Sector Care Program Justification Book, Volume 1, April 2026; service procurement justification books for Marine Corps line 6522, Navy Medical Support Equipment, and Army Combat Support Medical. Source for Information Management at $2.600 billion up $328.4 million, COMP procurement at $366.728 million, PSCP at $22.175 billion, and the three service field-medical lines totaling $376.3 million in FY2027 against $97.9 million in FY2025, as computed in "The Marine Corps Answered Him First," August 18, 2026. https://comptroller.war.gov/Portals/45/Documents/defbudget/FY2027/budget_justification/pdfs/09_Military_Health_System/MHS_PB27_J-Book-Vol1-COMP_PSCP.pdf

[CC31] House Armed Services Committee, FY2027 NDAA chairman's mark and member-level print, Sec. 715 as reported. Source for the proposed DHA Director authority over medical countermeasure procurement, pre-positioning, forward deployment, logistics, storage, and sustainment using COMP and Army medical readiness funds. Proposed text, not law; section numbering in flux between the print and the reported bill. https://armedservices.house.gov/uploadedfiles/fy27_ndaa_mlp_print-_final.pdf

[CC32] Defense Logistics Agency, "DLA successfully tests medical supply chain for future warfighting readiness," July 2026. Source for the ARMOR wargame with more than 120 federal and industry partners and its findings on foreign dependencies and production limits. Not independently fetched this session. https://www.dla.mil/About-DLA/News/News-Article-View/Article/4558955/dla-successfully-tests-medical-supply-chain-for-future-warfighting-readiness/

[CC33] U.S. Army Acquisition Support Center, "Fail Forward and Pivot," and Clark, Malek, and Mountney, "The 'LLC' of Acquisition Streamlining," March 25, 2019. Source for the VAMP modular contracting approach with eight pharmaceutical partners and for the atropine auto-injector and midazolam approvals. https://asc.army.mil/web/news-the-llc-of-acquisition-streamlining-lessons-for-accelerating-product-development/

[CC34] Trade and aggregator coverage of the Swingtide sole-source acquisition advisory extension on the MHS GENESIS restructure, August 2026, and GovConWire, "AIX Tech wins $225M DHA contracting and acquisition support IDIQ," March 2026. Reported; verify award status and scope before mapping OCI. https://www.govconwire.com/articles/aix-tech-dha-acquisition-support-idiq

[CC35] GovConWire, "DHA awards 12 spots on $300M PEO DHMS Deployment Solutions IDIQ," summer 2026. Source for the twelve awardees including Leidos, the $300 million shared ceiling, 29 offers, and the August 2026 through August 2031 ordering period. Reported; verify in the federal award record. https://www.govconwire.com/articles/dha-peo-dhms-deployment-support

[CC36] SAM.gov, IRMAC Pacific HT941026R2001, 8(a) set-aside, NAICS appeal filed May 29, 2026, re-posted August 11, 2026 with September 2026 responses; Washington Technology, "DHA chooses 6 for $2.4B global IT services vehicle," July 2023 (GSP total small business set-aside). https://sam.gov/workspace/contract/opp/806a712e51f84351a0f3cfb439d52a5a/view

[CC37] Government Accountability Office, GAO-25-106988, military medical personnel. Source for the projected shortfall exceeding 8,000 clinical military medical personnel with shortfalls anticipated until at least 2027, and DHA's report that it could not hire civilians to fill the gap. https://files.gao.gov/reports/GAO-25-106988/index.html

[CC38] GAO bid protest docket entries for DHA competitions filed in 2026, each dismissed within roughly two to five weeks; GovConFeed, "GAO 2025 Bid Protest Annual Report," May 2026, for the FY2025 governmentwide figures of 1,688 filings, 53 sustains, and a 14 percent sustain rate across 380 merits decisions. https://govconfeed.com/article/gao-2025-bid-protest-annual-report-trends-may-2026

Sources verified as of September 4, 2026.